Brokerages have given Intellia Therapeutics, Inc. (NASDAQ:NTLA) an average rating of “Moderate Buy.”

The nineteen analysts currently following Intellia Therapeutics, INC (NASDAQ: NTLA) have reportedly given the company’s shares a rating of “Moderate Buy” as the consensus recommendation for the investment strategy, as reported by Bloomberg.com.

Investment professionals have made six recommendations regarding the stock: three to buy the stock, four to hold the stock, and one to sell the stock.

The financial experts who have provided ratings on the stock over the past year have concluded that the share price is likely to meet or exceed an average price target of $80 over the subsequent year.

Recently, several analysts who have been monitoring NTLA stock have published reports on the stock. Robert W.

Baird lowered the price target for Intellia Therapeutics from $58.00 to $42.00 and assigned the company a “neutral” rating in a research note that was published on Friday, February 24. JMP Securities downgraded Intellia Therapeutics from an “outperform” rating to a “market perform” rating on Thursday, January 19, and announced their decision in a published research note that day.

In a research report made public on January 4, 2019, Wells Fargo & Company downgraded their “overweight” rating on shares of Intellia Therapeutics.

It decreased its price objective on those shares from $135.00 to $120.00. Oppenheimer lowered their price objective for Intellia Therapeutics in a research report that was published on Friday, February 24.

The new price objective is $93.00, down from $115.00 previously.
Additionally, they did not change their rating of “outperform” for the business.

In a research note that was distributed on Friday, February 24, Raymond James lowered their price objective on shares of Intellia Therapeutics from $120.00 to $94.00.

The note was about the company’s performance.

Despite this modification, Raymond James has continued to assign an “outperform” rating to the company.
On January 4, the Chief Executive Officer of the company, John M.

Leonard, sold 6,673 shares of the company’s stock.

This is another development that is relevant to this topic.

The number of shares traded came to 248,302.33 and were sold at an average price of $37.21 per share.

This resulted in the accumulation of cash.

The company’s CEO will own 766,825 shares as soon as the deal is finalized.

Based on the current stock price, these shares have a value of $28,533,558.25.

Because of the filing made with the SEC, information regarding the transaction is now available to the general public. On the website of the SEC, you can locate this particular file. Glenn Goddard, who serves as the Chief Financial Officer of Intellia Therapeutics, is said to have sold 2,427 shares of the company’s stock on January 4, according to reports from other sources concerning the company.

There was a total sale of shares worth $90,308.67, with the average price that each share was purchased for being $37.21.

As a result of the successful completion of the transaction, the chief financial officer now owns 15,404 shares of the company, which have a value of $573,182.84. Following this link, you will be taken to the SEC filing in which the transaction was discussed in greater detail.

Additionally, on January 4, the Chief Executive Officer of Intellia Therapeutics, John M.

Leonard, sold 6,673 shares of the company’s stock.

As a result of the purchase of the shares at an average price of $37.21, the transaction had a total value of 248,302.33 dollars. Following the completion of the acquisition, the CEO now owns a total of 766,825 shares, estimated to be worth approximately $28,533,558.25.

Disclosures related to the sale might be found in this website section.

Insiders of the company sold 11,608 shares of company stock during the preceding quarter for a total price of $431,934, including commissions. 2.60 corporate insiders own a percent of the total number of shares in the company.
During the most recent period, several hedge funds and other institutional investors bought and sold NTLA shares. Other types of institutional investors have also bought and sold NTLA shares.

During the third quarter, Eqis Capital Management INC increased the amount of Intellia Therapeutics stock that it held by 5.1% to reflect the company’s recent acquisitions.

As a result of the acquisition of 210 additional shares during the most recent quarter, Eqis Capital Management INC now has a total of 4,345 shares of the company’s stock, which has a value of $243,000 and gives the company a market capitalization of During the third fiscal quarter, Xponance INC grew its ownership of Intellia Therapeutics stock by 5.2%.

During the relevant period, Xponance INC purchased an additional 210 shares of company stock, bringing their total purchase of company stock during the relevant period to 4,250 shares with a value of $238,000.

During the second quarter, Steward Partners Investment Advisors LLC increased the percentage of Intellia Therapeutics stock they owned by 10.2%. Steward Partners Investment Advisory LLC now holds 2,368 shares of the company’s stock, which has a value of $123,000 after acquiring an additional 220 shares during the most recent fiscal quarter. Steward Partners Investment Advisory LLC is a registered investment advisory firm.

During the third quarter, Amalgamated Bank increased the amount of Intellia Therapeutics stock that is owned by 2.0%, bringing the total amount to 100%.

After purchasing 222 additional shares during the most recent quarter, Amalgamated Bank now directly owns 11,352 shares.

These shares are $635,000, making the total value of Amalgamated Bank’s shareholdings in the company $635,000.

The outcomes of business operations for the third quarter at the Zurich Kantonalbank Zurich Cantonalbank has increased its stake in Intellia Therapeutics by purchasing additional shares, bringing their total stake to 1.6%. Zurcher Kantonalbank, a financial institution based in Switzerland, currently owns 15,777 shares of the company’s stock, which have a value of $883,000.

This is because the financial institution purchased 247 additional shares during the relevant period.

The ownership of the company’s stock is held, to the extent of 85.61 percent, by institutional investors.

Thursday was NASDAQ’s first day: NTLA was available for trading, and the opening price was $40.75.

Both the price-to-earnings ratio of the company, which is currently at -6.59, and its beta value are currently at 1.90.

The company has a market capitalization of $3.59 billion, and the opening price was $40.75.

Both the price-to-earnings ratio of the company, which is currently at -6.59, and its beta value are currently at 1.90.

The company currently has a market capitalization of $3.59 billion.

The stock is currently trading at $38.64 on its simple moving average for the past 50 days, while its simple moving average for the past 200 days is $48.04, respectively. Over the past 52 weeks, the price of a share of Intellia Therapeutics has ranged from as low as $32.44 to as high as $86.16, respectively.
On Thursday, February 23, the most recent quarterly earnings report for Intellia Therapeutics (NASDAQ: NTLA) was made public for the investing community to see.

The quarterly earnings per share came in at $1.40, which was in line with the estimate reached by most market analysts, who had reached a consensus of $1.40.

Intellia Therapeutics had a return on equity of 48.70 percent, but the company had a net margin that was negative 909.78 percent of the company’s revenue.

The market had predicted that the company would bring in $10.71 million in revenue for the quarter. Still, the actual amount that the company brought in, $13.60 million, was significantly higher than what was expected by the market. Compared to the previous year, the company had earnings of $1.09 per share during the same period. Compared to the same period the previous year, Intellia Therapeutics’ quarterly sales experienced an increase of 5.4%.

Equity research analysts forecast that Intellia Therapeutics will post a loss of -5.78 cents per share in revenue for the current fiscal year.

Utilizing the CRISPR/Cas9 system, Intellia Therapeutics, INC, a company that edits genomes and is currently engaged in the phase of clinical testing, develops curative treatments.

The CRISPR/Cas9 method is revolutionizing medicine by enabling the creation of treatments that can permanently edit and/or correct disease-associated genes in the human body with a single course of treatment.

Additionally, this method enables the modification of cells that can treat oncological and immunological disorders.

Read more here: Source link